by The global Human Immunoglobulin (pH4) for Intravenous Injection market has witnessed significant growth due to the increasing prevalence of various primary immunodeficiency disorders and neurological disorders. Human Immunoglobulin, also known as intravenous immunoglobulin (IVIG), contains concentrated antibodies purified from human plasma. It acts as replacement therapy for patients suffering from immune deficiencies leading to recurrent infections. IVIG therapy has demonstrated efficacy in treating several chronic inflammatory demyelinating polyneuropathies and Guillain-Barre syndrome. IVIG products available in the market differ based on their purity, process of manufacture, and pH levels during formulation. pH4 IVIG products have shown improved stability and tolerance in patients compared to conventional IVIG products.
The global Human Immunoglobulin (pH4) for Intravenous Injection Market is estimated to be valued at US$ 5.2 billion in 2023 and is expected to exhibit a CAGR of 16% over the forecast period 2023-2031, as highlighted in a new report published by Coherent Market Insights.
Market key trends: One of the key trends in the Human Immunoglobulin (pH4) for Intravenous Injection market is the rising adoption of subcutaneous immunoglobulin (SCIG) therapy. SCIG administration allows patients to self-administer immunoglobulin therapy at home, reducing hospital visits. Compared to IVIG therapy, SCIG offers benefits such as consistent serum immunoglobulin levels, reduced infusion time, and improved tolerability. Several pharmaceutical companies are focusing on developing SCIG formulations to gain a competitive edge in the market. For instance, in 2022, Takeda Pharmaceutical received FDA approval for its Hyqvia SCIG formula to treat primary immunodeficiency in adults. Another important trend is the increasing collaborations and acquisitions between key players to expand their product portfolios and geographic presence.
Porter’s Analysis
Threat of new entrants: The Biologics industry requires considerable capital investments and regulatory protocols that pose significant entry barriers for new players.
Bargaining power of buyers: The presence of several established players in the market has increased competition and provided buyers with greater purchasing power and price leverage.
Bargaining power of suppliers: The key raw materials required are human plasma which are supplied by only a few plasma fractionation companies globally increasing their bargaining power.
Threat of new substitutes: There are no close substitutes for human immunoglobulin therapy currently hence threat from substitutes is low.
Competitive rivalry: The human immunoglobulin market is highly competitive with major players competing on the basis of product quality, reliability of supply and pricing.
Key Takeaways
The global Human Immunoglobulin (pH4) for Intravenous Injection market is expected to witness high growth over the forecast period.
Regional analysis: North America dominates the global human immunoglobulin market supported by rising prevalence of autoimmune diseases and increasing plasma collection in the region. The US and Canada are major revenue generators while Mexico is expected to witness highest growth.
Key players: Key players operating in the Human Immunoglobulin (pH4) for Intravenous Injection market include Takeda, CSL Behring, Grifols, Octapharma and Kedrion Biopharma. Takeda is a major supplier with extensive geographical presence. CSL Behring offer a diversified product portfolio.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
